MiNK Therapeutics (NASDAQ:INKT) Issues Earnings Results, Beats Estimates By $0.14 EPS

MiNK Therapeutics (NASDAQ:INKT) announced its quarterly earnings data on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14, FiscalAI reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK highlighted durable clinical signals in oncology, including median overall survival >23 months and complete remissions beyond two years in heavily pretreated solid tumors, supported by coordinated immune activation without systemic toxicity.
• Early ARDS/hypoxemic pneumonia results showed tolerability at 1 billion cells, apparent reduction in harmful inflammation, pathogen clearance and much higher survival in treated patients (70% vs ~10% historical controls), and MiNK is initiating a randomized phase II trial with initial data expected in H2 2026.
• The company emphasized capital efficiency and non-dilutive funding—NIH/NIAID, Mary Goos, C‑Further and other sources—while reporting cash of $13.4M at year-end plus $3M raised post-year-end, which management says extends runway into 2026.
• Despite cost reductions, MiNK reported a full‑year net loss of $12.5M and a cash runway that currently extends only through 2026, meaning additional financing may be required to support multi‑program development and larger randomized trials.
• Management said no formal collaborations have been announced for combination trials (e.g., IL‑15 agonists) despite some trials appearing publicly, noting ongoing discussions—investors should treat combination reports as unconfirmed until official announcements.

MiNK Therapeutics Trading Up 0.1%

INKT stock opened at $10.53 on Wednesday. The firm has a 50-day moving average price of $10.95 and a 200-day moving average price of $12.24. MiNK Therapeutics has a 12 month low of $6.34 and a 12 month high of $76.00. The stock has a market capitalization of $49.39 million, a P/E ratio of -3.48 and a beta of 0.35.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $35.00.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC boosted its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,247 shares of the company’s stock after purchasing an additional 1,441 shares during the period. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent quarter. 2.87% of the stock is owned by hedge funds and other institutional investors.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.